The promise of cell and gene therapy lies in one-time, potentially curative treatments. The challenge is manufacturing them. Behind every approved therapy sits a complex network of viral vector production, specialized manufacturing, cryogenic logistics and reimbursement infrastructure that determines whether a living medicine can actually reach a patient. Cell and gene therapies have delivered some … Inside Cell and Gene Therapy Manufacturing: Who Actually Builds the Living Medicines Read More » To access this post, you must purchase Individual Subscriber Yearly.